System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maël Heiblig is an expert in Hematology at Centre Hospitalier Lyon Sud (France). As of October 2026, ScienceLeadR ranks Maël Heiblig in the top 1% of experts worldwide for Leukemia. Maël Heiblig has authored 197 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 29 of them ongoing. SLR score: 1,359 (community average: 125). How the SLR is computed.

LeadR Profile

Maël Heiblig Centre Hospitalier Lyon Sud France
1 359 ScienceLeadR Reputation 1359

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2014 - 2026
Source: PubMed

CNRS

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 197

Citations

Citations: 2 262 1st author: 35 Last author: 17 Unique author: 0

Main journals

Blood 46
Hemasphere 10
Leukemia 9
Rev Med Interne 9
CL LYMPH MYELOM LEUK 6

Best Journals

J Clin Oncol 4
Cancer Cell 1
J Hematol Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.
PMID 42697860 — hematology, cytarabine, drug therapy, azacitidine, therapeutics, cytogenetics, salvage therapy, chemotherapy		Br J Haematol20260
Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series.
PMID 42498149 — adrenal cortex hormones, eosinophils, hypereosinophilic syndrome, immune system diseases		Clin Immunol20260
Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
PMID 42507967 — medical oncology		J Clin Oncol Top journal20260
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.
PMID 42469476 — registries, leukemia, azacitidine		Leukemia20260
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI).
PMID 42439317 — arthritis, research		Arthritis Care Res (Hoboken)20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 2 13
N/A 9
Phase 1/Phase 2 8
Phase 3 7
Phase 1 3
Phase 2/Phase 3 1

By status:

Recruiting 25
Active not recruiting 5
Not yet recruiting 5
Completed 3
Unknown 2
Terminated 1

By type:

Interventional 35
Observational 6

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 3
multicentric5to9 3
multicentricup10 32

Main Topics

Ongoing Clinical Trials

29 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Pivotal Open label Phase 3 Clinical Study of QTX 2101 in Adult Patients With Acute Promyelocytic Leukemia
2025-524810-28-00 — safety, leukemia, promyelocytic, acute, leukemia, therapeutics, tretinoin		Phase 3Recruiting2026
A Phase 1 2 study of Enzomenib (DSP 5336) in Patients with Acute leukemia
2022-502741-10-00 — hematologic neoplasms, leukemia, mutation		Phase 1/Phase 2Recruiting2024
Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment naive blastic plasmacytoid dendritic cell neoplasm patients
2024-511003-42-00 — skin, cells, safety, neoplasms, therapeutics, dendritic cells		Phase 2Recruiting2025
A study to assess the effectiveness and safety of pacritinib in patients with VEXAS syndrome (PAXIS)
2024-516347-41-00 — safety		Phase 2Recruiting2025
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy
2024-512753-24-00 — genes, leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS